Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Mechanisms of resistance to CYP17A1 inhibitors in castrate resistant prostate cancer].

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie - 1 Oct 2013

Ripert T, Crouzet S, Ploussard G, De La Taille A, Robert G

Abstract excerpt

INTRODUCTION: Abiraterone acetate has increased the overall survival of patients with metastatic castration-resistant prostate cancer. However, despite an initial response to treatment, many patients develop resistance to the drug. In this paper we present different hypotheses that may explain th...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Androgen Antagonists
Share to Androstadienes
Share to Gene Expression Regulation, Enzymologic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Prostate-Specific Antigen

Share to Prostatic Neoplasms, Castration-Resistant

Share to Receptors, Androgen

Share to Steroid 17-alpha-Hydroxylase

Share to Survival Analysis

Source

Identifiers

PMID: 24314735
DOI: 10.1016/S1166-7087(13)70042-3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-24314735-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Mechanisms of resistance to CYP17A1 inhibitors in castrate resistant prostate cancer].PMID 24314735Read ↗

Resistance to second generation antiandrogens in prostate cancer: pathways and mechanismsSemantic proximity Read ↗

Understanding and overcoming the mechanisms of primary and acquired resistance to abiraterone and enzalutamide in castration resistant prostate cancer.Semantic proximity Read ↗

Overcoming castration resistance in prostate cancer.Semantic proximity Read ↗

Androgen receptor targeting drugs in castration‐resistant prostate cancer and mechanisms of resistanceSemantic proximity Read ↗

Novel hormone therapies for advanced prostate cancer: Understanding and countering drug resistanceSemantic proximity Read ↗

Targeting extra-gonadal androgens in castration-resistant prostate cancer.Semantic proximity Read ↗

Minireview: Androgen Metabolism in Castration-Resistant Prostate CancerSemantic proximity Read ↗

Overcoming drug resistance in castrate-resistant prostate cancer: current mechanisms and emerging therapeutic approachesSemantic proximity Read ↗

Androgen Receptor Rearrangement and Splicing Variants in Resistance to Endocrine Therapies in Prostate CancerSemantic proximity Read ↗

[The concept and mechanisms of castration-resistant prostate cancer].Semantic proximity Read ↗

Connecting Gene Variation to Treatment Outcomes in Metastatic Castration-Resistant Prostate Adenocarcinoma: Insights into Second-Generation Androgen Receptor Axis-Targeted Therapies.Semantic proximity Read ↗

The association between missense polymorphisms in SRD5A2 and HSD3B1 and treatment failure with abiraterone for castration-resistant prostate cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.